Local Radiopharmaceutical Production and Supply

The contract requires the local production and daily supply of short-half-life radiopharmaceuticals, including In-111 oxyquinoline and Tc-99m compounds, to WBAMC at Fort Bliss. Due to the rapid decay of these isotopes, all manufacturing must occur on-site or in close proximity to ensure timely delivery and clinical usability. Both routine daily shipments and emergency STAT deliveries are mandated to support patient care needs without interruption. The nature of the work necessitates a facility equipped for radioisotope handling, sterile compounding, and rapid logistics to meet the stringent temporal requirements inherent in nuclear medicine. The contract is structured as a subcontract under the Department of Defense, with performance centered at Fort Bliss, and response submissions are due by May 8, 2026.